Pharm-Olam Experts to Present Live Seminar on Evolution of Response Evaluation in Oncology Trials
Global clinical research experts Yamin “Mo” Khan, PhD, and Dhiraj Abhyankar, MD will host an interactive discussion and seminar on the Evolution of Response Evaluation in Oncology Trials. The free public forum will be held at 11 a.m. Eastern Standard Time on Thursday, March 30 via webinar.
“Oncology drug development is evolving faster today than ever before,” said Dr. Abhyankar, Director, Scientific Development, at Pharm-Olam International. “The advent of new therapies and emerging trends in immuno-oncology have changed the standards by which tumor response to therapies must be measured.”
To remain competitive, “it’s critical that Sponsors remain aware of the very latest trends” in response evaluation, Dr. Abhyankar added.
The presenter for this webinar will be Dr. Abhyankar, a medical oncologist, who boasts over a decade of experience in oncology development across all phases of clinical research. In his role at Pharm-Olam, a leading global mid-size CRO, Dr. Abhyankar provides strategic guidance with respect to Early Phase oncology research efforts. He also provides medical support as treatments move through the development process. Dr. Khan will act as the session moderator.
The free webinar is recommended for Medical Officers, Principal Investigators and Global Trial Managers involved in oncology development programs. To participate, advance web registration is required and can be completed at http://www.pharm-olam.com/webinar/response-evaluation-in-oncology-trials.
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit www.pharm-olam.com.